

## Supplementary Online Content

Giugliano RP, Keech A, Murphy SA, et al. Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial. *JAMA Cardiol*. Published online November 8, 2017. doi:10.1001/jamacardio.2017.3944

**eTable 1.** Efficacy Outcomes With Evolocumab vs Placebo Stratified by Baseline LDL-C Level

**eTable 2.** Efficacy Outcomes With Evolocumab vs Placebo Stratified by Potency of Background Statin Treatment

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1.** Efficacy Outcomes With Evolocumab vs Placebo Stratified by Baseline LDL-C Level

Outcome	Baseline LDL-C <70 mg/dL <sup>a</sup> (N=2034)			Baseline LDL-C ≥70 mg/dL (N=25529)			P <sub>INT</sub>
	Evolocumab (N=1030)	Placebo (N=1004)	Hazard Ratio (95% CI)	Evolocumab (N=12754)	Placebo (N=12775)	Hazard Ratio (95% CI)	
Primary endpoint <sup>b</sup>	86 (8.3)	106 (10.6)	0.80 (0.60-1.07)	1258 (9.9)	1457 (11.4)	0.86 (0.79-0.92)	0.65
Key secondary endpoint <sup>c</sup>	48 (4.7)	68 (6.8)	0.70 (0.48-1.01)	768 (6.0)	945 (7.4)	0.81 (0.73-0.89)	0.44
Other endpoints							
Cardiovascular death	14 (1.4)	14 (1.4)	0.97 (0.46-2.04)	237 (1.9)	226 (1.8)	1.05 (0.87-1.26)	0.88
Myocardial infarction	25 (2.4)	43 (4.3)	0.58 (0.35-0.94)	443 (3.5)	596 (4.7)	0.74 (0.65-0.84)	0.32
Stroke	17 (1.7)	20 (2.0)	0.85 (0.44-1.62)	190 (1.5)	242 (1.9)	0.78 (0.65-0.95)	0.84
Hospitalized for unstable angina	16 (1.6)	19 (1.9)	0.84 (0.43-1.64)	220 (1.7)	220 (1.7)	1.00 (0.83-1.20)	0.63
Coronary revascularization	51 (5.0)	65 (6.5)	0.78 (0.54-1.13)	708 (5.6)	900 (7.0)	0.78 (0.71-0.86)	0.97

Baseline LDL-C data were not available for one patient randomized to placebo.

To convert LDL-C to millimoles per liter, multiply by 0.0259.

Data shown are n (%)

<sup>a</sup> These patients either had a final screening LDL-C of at least 70 mg/dL or a final screening non-HDL-C of at least 100 mg/dL.

<sup>b</sup> Cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization

<sup>c</sup> Cardiovascular death, myocardial infarction, stroke

**eTable 2.** Efficacy Outcomes With Evolocumab vs Placebo Stratified by Potency of Background Statin Treatment

Outcome	Maximal Potency Background Statin			Submaximal Potency Background Statin			P <sub>INT</sub>
	Evolocumab (N=3758)	Placebo (N=3775)	Hazard Ratio (95% CI)	Evolocumab (N=10026)	Placebo (N=10005)	Hazard Ratio (95% CI)	
Primary endpoint <sup>a</sup>	421 (11.2)	489 (13.0)	0.86 (0.75-0.98)	923 (12.4)	1074 (13.9)	0.85 (0.78-0.93)	0.88
Key secondary endpoint <sup>b</sup>	246 (6.5)	315 (8.3)	0.78 (0.66-0.92)	570 (7.9)	698 (9.7)	0.81 (0.72-0.90)	0.71
Other endpoints							
Cardiovascular death	74 (2.0)	67 (1.8)	1.11 (0.80-1.54)	177 (2.6)	173 (2.3)	1.02 (0.83-1.26)	0.67
Myocardial infarction	141 (3.8)	222 (5.9)	0.63 (0.51-0.78)	327 (4.3)	417 (5.8)	0.78 (0.67-0.90)	0.11
Stroke	60 (1.6)	60 (1.6)	1.00 (0.70-1.44)	147 (2.3)	202 (2.8)	0.72 (0.58-0.89)	0.11
Hospitalized for unstable angina	75 (2.0)	90 (2.4)	0.84 (0.62-1.14)	161 (2.4)	149 (1.9)	1.08 (0.86-1.35)	0.20
Coronary revascularization	248 (6.6)	316 (8.4)	0.78 (0.66-0.93)	511(6.5)	649 (8.8)	0.78 (0.69-0.88)	0.95

Maximal potency statin = atorvastatin 80 mg or rosuvastatin 40 mg daily.

Data shown are n (%).

<sup>a</sup>Cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization

<sup>b</sup>Cardiovascular death, myocardial infarction, stroke